JP2012514997A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514997A5
JP2012514997A5 JP2011545812A JP2011545812A JP2012514997A5 JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5 JP 2011545812 A JP2011545812 A JP 2011545812A JP 2011545812 A JP2011545812 A JP 2011545812A JP 2012514997 A5 JP2012514997 A5 JP 2012514997A5
Authority
JP
Japan
Prior art keywords
monovalent antibody
recombinant monovalent
region
recombinant
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011545812A
Other languages
English (en)
Japanese (ja)
Other versions
JP5755148B2 (ja
JP2012514997A (ja
Filing date
Publication date
Priority claimed from EP09290029A external-priority patent/EP2210902A1/en
Application filed filed Critical
Publication of JP2012514997A publication Critical patent/JP2012514997A/ja
Publication of JP2012514997A5 publication Critical patent/JP2012514997A5/ja
Application granted granted Critical
Publication of JP5755148B2 publication Critical patent/JP5755148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011545812A 2009-01-14 2010-01-13 組換え一価抗体 Active JP5755148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290029.9 2009-01-14
EP09290029A EP2210902A1 (en) 2009-01-14 2009-01-14 Recombinant monovalent antibodies
PCT/IB2010/000196 WO2010082136A1 (en) 2009-01-14 2010-01-13 Recombinant monovalent antibodies

Publications (3)

Publication Number Publication Date
JP2012514997A JP2012514997A (ja) 2012-07-05
JP2012514997A5 true JP2012514997A5 (https=) 2013-02-28
JP5755148B2 JP5755148B2 (ja) 2015-07-29

Family

ID=40435756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545812A Active JP5755148B2 (ja) 2009-01-14 2010-01-13 組換え一価抗体

Country Status (5)

Country Link
US (2) US9587023B2 (https=)
EP (2) EP2210902A1 (https=)
JP (1) JP5755148B2 (https=)
CA (2) CA2749627C (https=)
WO (1) WO2010082136A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
LT2536764T (lt) * 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2586028A1 (en) * 2004-11-01 2006-05-11 Medimmune, Inc. Ultra high throughput capture lift screening methods
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US7846439B2 (en) * 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
LT2536764T (lt) * 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai

Similar Documents

Publication Publication Date Title
JP2012514997A5 (https=)
JP5755148B2 (ja) 組換え一価抗体
JP2020508655A5 (https=)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2012501669A5 (https=)
JP2022512684A5 (https=)
JP2015519055A5 (https=)
RU2019100481A (ru) Биспецифические антитела-ингибиторы контрольных точек
JP2019031529A5 (https=)
JP2017504578A5 (https=)
HK1207575A1 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
RU2013140350A (ru) Антитела против человеческого il33r и их применение
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
JP2012501670A5 (https=)
RU2012142231A (ru) Антитела против csf-1r человека и их применение
JP2019525738A5 (https=)
JP2013529084A5 (https=)
JP2013545455A5 (https=)
FI3561057T3 (fi) Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä
JP2014518883A5 (https=)
RU2014114172A (ru) Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
JP2012525829A5 (https=)
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
JP2010536396A5 (https=)
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity